全文获取类型
收费全文 | 123篇 |
免费 | 16篇 |
国内免费 | 1篇 |
专业分类
140篇 |
出版年
2021年 | 3篇 |
2018年 | 2篇 |
2017年 | 5篇 |
2016年 | 6篇 |
2015年 | 5篇 |
2014年 | 4篇 |
2013年 | 4篇 |
2012年 | 6篇 |
2011年 | 5篇 |
2010年 | 10篇 |
2009年 | 8篇 |
2008年 | 9篇 |
2007年 | 6篇 |
2006年 | 3篇 |
2005年 | 2篇 |
2004年 | 2篇 |
2003年 | 4篇 |
2002年 | 1篇 |
2001年 | 5篇 |
2000年 | 1篇 |
1999年 | 1篇 |
1998年 | 10篇 |
1997年 | 6篇 |
1996年 | 5篇 |
1995年 | 1篇 |
1994年 | 4篇 |
1993年 | 6篇 |
1990年 | 3篇 |
1989年 | 1篇 |
1987年 | 2篇 |
1983年 | 2篇 |
1982年 | 1篇 |
1981年 | 1篇 |
1980年 | 1篇 |
1979年 | 1篇 |
1978年 | 1篇 |
1977年 | 1篇 |
1975年 | 2篇 |
排序方式: 共有140条查询结果,搜索用时 0 毫秒
91.
The mTOR inhibitor everolimus (RAD001, Afinitor) is an orally active anticancer agent. Everolimus demonstrates growth-inhibitory activity against a broad range of tumor cell histotypes in vitro and has the capacity to retard tumor growth in preclinical tumor models in vivo through mechanisms directed against both the tumor cell and the solid tumor stroma components. These properties have rendered it to be a clinically active drug, with subsequent registration in renal cell carcinoma (Motzer et al. [2008]. Lancet 372, 449–456) as well as showing strong potential as a combination partner (André F et al. [2008]. J Clin Oncol 26. Abstract 1003). Although everolimus has a high specificity for its molecular target, the ubiquitous nature of mTOR and the multifactorial influence that mTOR signaling has on cell physiology have made studies difficult on the identification and validation of a biomarker set to predict and monitor drug sensitivity for clinical use. In this review, a summary of the preclinical and clinical data relevant to biomarker development for everolimus is presented, and the advantages and problems of current biomarkers are reviewed. In addition, alternative approaches to biomarker development are proposed on the basis of examples of a combination of markers and functional noninvasive imaging. In particular, we show how basal levels of pAKT and pS6 together could, in principle, be used to stratify patients for likely response to an mTOR inhibitor. 相似文献
92.
I Prieto-Potín JA Roman-Blas MJ Martínez-Calatrava R Gómez R Largo Gabriel Herrero-Beaumont 《Arthritis research & therapy》2013,15(4):R81
Objective
The aim of this study was to determine whether hypercholesterolemia increases articular damage in a rabbit model of chronic arthritis.Methods
Hypercholesterolemia was induced in 18 rabbits by administrating a high-fat diet (HFD). Fifteen rabbits were fed normal chow as controls. Chronic antigen-induced arthritis (AIA) was induced in half of the HFD and control rabbits, previously immunized, by intra-articular injections of ovalbumin. After sacrifice, lipid and systemic inflammation markers were analyzed in blood serum. Synovium was analyzed by Krenn score, multinucleated cell counting, immunohistochemistry of RAM11 and CD31, and TNF-α and macrophage chemoattractant protein-1 (MCP-1) gene expression. Active bone resorption was assessed by protein expression of receptor activator of nuclear factor kappa-B ligand (RANKL), osteoprotegerin (OPG) and quantification of cathepsin K, contact surface and the invasive area of pannus into bone.Results
Rabbits receiving the HFD showed higher total serum cholesterol, HDL, triglycerides and CRP levels than rabbits fed a normal diet. Synovitis score was increased in HFD, and particularly in AIA and AIA + HFD groups. AIA + HFD synovium was characterized by a massive infiltration of RAM11+ cells, higher presence of multinucleated foam cells and bigger vascularization than AIA. Cathepsin K+ osteoclasts and the contact surface of bone resorbing pannus were also increased in rabbits with AIA + HFD compared with AIA alone. Synovial TNF-α and MCP-1 gene expression was increased in AIA and HFD rabbits compared with healthy animals. RANKL protein expression in AIA and AIA + HFD groups was higher compared with either HFD or normal groups.Conclusions
This experimental model demonstrates that hypercholesterolemia increments joint tissue damage in chronic arthritis, with foam macrophages being key players in this process. 相似文献93.
Sanchez D; Ganfornina MD; Gutierrez G; Bastiani MJ 《Molecular biology and evolution》1998,15(4):415-426
Arthropodan hemocyanins, prophenoloxidases (PPOs), and insect hexamerins
form a superfamily of hemolymph proteins that we propose to call the AHPH
superfamily. The evolutionary and functional relationships of these
proteins are illuminated by a new embryonic hemolymph protein (EHP) that is
expressed during early stages of development in the grasshopper embryo. EHP
is a 78-kDa soluble protein present initially in the yolk sac content, and
later in the embryonic hemolymph. Protein purification and peptide
sequencing were used to identify an embryonic cDNA clone coding for EHP. In
situ hybridization identifies hemocytes as EHP-expressing cells. As deduced
from the cDNA clone, EHP is a secreted protein with two potential
glycosylation sites. Sequence analysis defines EHP as a member of the AHPH
superfamily. Phylogenetic analyses with all the currently available AHPH
proteins, including EHP, were performed to ascertain the evolutionary
history of this protein superfamily. We used both the entire protein
sequence and each of the three domains present in the AHPH proteins. The
phylogenies inferred for each of the domains suggest a mosaic evolution of
these protein modules. Phylogenetic and multivariate analyses consistently
group EHP with crustacean hemocyanins and, less closely, with insect
hexamerins, relative to cheliceratan hemocyanins and PPOs. The grasshopper
protein rigorously preserves the residues involved in oxygen binding,
oligomerization, and allosteric regulation of the oxygen transport
proteins. Although insects were thought not to have hemocyanins, we propose
that EHP functions as an oxygen transport or storage protein during
embryonic development.
相似文献
94.
Leonardo Restivo Bjrn Gerlach Michael Tsoory Lior Bikovski Sylvia Badurek Claudia Pitzer Isabelle C KosBraun AnneLaure MJ MaussetBonnefont Jonathan Ward Michael Schunn Lucas PJJ Noldus Anton Bespalov Vootele Voikar 《EMBO reports》2021,22(12)
Academic Core Facilities are optimally situated to improve the quality of preclinical research by implementing quality control measures and offering these to their users. Subject Categories: Methods & Resources, Science Policy & PublishingDuring the past decade, the scientific community and outside observers have noted a concerning lack of rigor and transparency in preclinical research that led to talk of a “reproducibility crisis” in the life sciences (Baker, 2016; Bespalov & Steckler, 2018; Heddleston et al, 2021). Various measures have been proposed to address the problem: from better training of scientists to more oversight to expanded publishing practices such as preregistration of studies. The recently published EQIPD (Enhancing Quality in Preclinical Data) System is, to date, the largest initiative that aims to establish a systematic approach for increasing the robustness and reliability of biomedical research (Bespalov et al, 2021). However, promoting a cultural change in research practices warrants a broad adoption of the Quality System and its underlying philosophy. It is here that academic Core Facilities (CF), research service providers at universities and research institutions, can make a difference.It is fair to assume that a significant fraction of published data originated from experiments that were designed, run, or analyzed in CFs. These academic services play an important role in the research ecosystem by offering access to cutting‐edge equipment and by developing and testing novel techniques and methods that impact research in the academic and private sectors alike (Bikovski et al, 2020). Equipment and infrastructure are not the only value: CFs employ competent personnel with profound knowledge and practical experience of the specific field of interest: animal behavior, imaging, crystallography, genomics, and so on. Thus, CFs are optimally positioned to address concerns about the quality and robustness of preclinical research. 相似文献
95.
Stavropoulos-Kalinoglou A Metsios GS Panoulas VF Douglas KM Nevill AM Jamurtas AZ Kita M Koutedakis Y Kitas GD 《Arthritis research & therapy》2008,10(3):R59
Introduction
Rheumatoid arthritis (RA) is associated with altered metabolism leading to muscle wasting. In the general population, cigarette smoking is known to affect body composition by reducing fat and inhibiting muscle synthesis. Even though smoking has been implicated in the pathophysiology and progression of RA, its possible effects on body composition of such patients have not been studied. This cross-sectional study aimed to identify potential associations of smoking with body weight and composition of RA patients. 相似文献96.
97.
Mirjam MJ Jacobs Ronald G van den Berg Vivianne GAA Vleeshouwers Marcel Visser Rolf Mank Mariëlle Sengers Roel Hoekstra Ben Vosman 《BMC evolutionary biology》2008,8(1):145
Background
The secondary genepool of our modern cultivated potato (Solanum tuberosum L.) consists of a large number of tuber-bearing wild Solanum species under Solanum section Petota. One of the major taxonomic problems in section Petota is that the series classification (as put forward by Hawkes) is problematic and the boundaries of some series are unclear. In addition, the classification has received only partial cladistic support in all molecular studies carried out to date. 相似文献98.
99.
100.
Laura Sheard Nat MJ Wright Clive E Adams Nicole Bound Bruno Rushforth Roger Hart Charlotte NE Tompkins 《Trials》2009,10(1):1-5
Many research-funding agencies now require open access to the results of research they have funded, and some also require that researchers make available the raw data generated from that research. Similarly, the journal Trials aims to address inadequate reporting in randomised controlled trials, and in order to fulfil this objective, the journal is working with the scientific and publishing communities to try to establish best practice for publishing raw data from clinical trials in peer-reviewed biomedical journals. Common issues encountered when considering raw data for publication include patient privacy – unless explicit consent for publication is obtained – and ownership, but agreed-upon policies for tackling these concerns do not appear to be addressed in the guidance or mandates currently established. Potential next steps for journal editors and publishers, ethics committees, research-funding agencies, and researchers are proposed, and alternatives to journal publication, such as restricted access repositories, are outlined. 相似文献